Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
Open Access
- 23 February 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 14 (1), 72-80
- https://doi.org/10.1007/s10120-011-0009-5
Abstract
Irinotecan hydrochloride and S-1, an oral fluoropyrimidine, have shown antitumor activity against advanced gastric cancer as single agents in phase I/II studies. The combination of irinotecan and S-1 (IRI-S) is also active against advanced gastric cancer. This study was conducted to compare the efficacy and safety of IRI-S versus S-1 monotherapy in patients with advanced or recurrent gastric cancer.Keywords
This publication has 37 references indexed in Scilit:
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerThe New England Journal of Medicine, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineThe New England Journal of Medicine, 2007
- Phase II Study of a Combination of Irinotecan and S-1 in Patients with Advanced Gastric Cancer (OGSG0002)Oncology, 2007
- Gastric cancer treated in 1991 in Japan: data analysis of nationwide registryGastric Cancer, 2006
- Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancerBritish Journal of Cancer, 2006
- Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002)Japanese Journal of Clinical Oncology, 2005
- Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancerInternational Journal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998